Insights Into Hodgkin Lymphoma (HL)

Perspectives of community physicians from across the US on the management Hodgkin lymphoma (HL) with regard to clinical and nonclinical factors impacting treatment selection

Northeast – August 20, 2022

Faculty Chair

Barbara Pro, MD

MD Anderson Cancer Center, Houston, TX, USA

Midwest – September 17, 2022

Faculty Chair

Joanna Rhodes, MD

Northwell Health, New York, NY, USA

Northwest – November 19, 2022

Faculty Chair

Krish Patel, MD

Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA

More Information

  • Philadelphia, PA
  • New Jersey, New York, Pennsylvania

More Information

  • Chicago, IL
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Report

Start discovering the insights

View Report


  • Assess advisors’ current management of cHL
  • Gain insights into advisors’ perceptions of available therapies and understanding of data
  • Understand impact of pathways and other nonclinical factors that may affect treatment selection


  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.